Auvelity: Mechanism of Action?
On Aug 19, 2022 Axsome Therapeutics announced the FDA Approval of Auvelity, as the first and Only Oral NMDA Receptor Antagonist for the treatment of Major Depressive Disorder in adults.
Watch the following YouTube video on
Auvelity: Mechanism of Action
(CORRECTION: In the mechanism section, it is SIGMA RECEPTOR AGONISM & NOT ANTAGONISM)
DETAILED LECTURE FOR ACADEMY MEMBERS:
AUVELITY: NEW ANTIDEPRESSANT FOR MDD
ACADEMY
JOIN EMAIL NEWSLETTER (FREE):
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
© 2024 All Rights Reserved.
